A phase III, double-blind, randomized, placebo-controlled study of JBT-101 in diffuse cutaneous systemic sclerosis
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Ajulemic acid (Primary)
- Indications Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Sponsors Corbus Pharmaceuticals
- 08 Nov 2017 According to a Corbus Pharmaceuticals media release, the company expects to report topline results before the end of 2019.
- 23 Oct 2017 According to a Corbus Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
- 09 Aug 2017 Planned number of patients changed from 270 to 350 according to a Corbus Pharmaceuticals media release.